

Tao Che

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3171213/publications.pdf>

Version: 2024-02-01

27
papers

3,442
citations

393982

19
h-index

525886

27
g-index

32
all docs

32
docs citations

32
times ranked

4411
citing authors

#	ARTICLE	IF	CITATIONS
1	Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain. <i>Molecules</i> , 2022, 27, 595.	1.7	11
2	Advances in the Treatment of Chronic Pain by Targeting GPCRs. <i>Biochemistry</i> , 2021, 60, 1401-1412.	1.2	12
3	Predicted Mode of Binding to and Allosteric Modulation of the μ -Opioid Receptor by Kratom's Alkaloids with Reported Antinociception <i>In Vivo</i> . <i>Biochemistry</i> , 2021, 60, 1420-1429.	1.2	26
4	Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site. <i>ELife</i> , 2021, 10, .	2.8	40
5	Biased ligands at opioid receptors: Current status and future directions. <i>Science Signaling</i> , 2021, 14, .	1.6	58
6	Structural Insights Accelerate the Discovery of Opioid Alternatives. <i>Annual Review of Biochemistry</i> , 2021, 90, 739-761.	5.0	33
7	Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom. <i>ACS Chemical Neuroscience</i> , 2021, 12, 2661-2678.	1.7	20
8	A promising chemical series of positive allosteric modulators of the μ -opioid receptor that enhance the antinociceptive efficacy of opioids but not their adverse effects. <i>Neuropharmacology</i> , 2021, 195, 108673.	2.0	16
9	A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13873-13892.	2.9	33
10	Nanobodies as sensors of GPCR activation and signaling. <i>Methods in Cell Biology</i> , 2021, 166, 161-177.	0.5	1
11	Synthesis and Pharmacological Evaluation of Fluorinated Quinoxaline-Based μ -Opioid Receptor (KOR) Agonists Designed for PET Studies. <i>ChemMedChem</i> , 2020, 15, 1834-1853.	1.6	5
12	Structure of a Hallucinogen-Activated Gq-Coupled 5-HT _{2A} Serotonin Receptor. <i>Cell</i> , 2020, 182, 1574-1588.e19.	13.5	270
13	TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. <i>Nature Chemical Biology</i> , 2020, 16, 841-849.	3.9	281
14	Enantiomerically Pure Quinoline-Based μ -Opioid Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation. <i>ChemMedChem</i> , 2020, 15, 1408-1420.	1.6	2
15	Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. <i>Nature</i> , 2020, 579, 609-614.	13.7	184
16	Nanobody-enabled monitoring of kappa opioid receptor states. <i>Nature Communications</i> , 2020, 11, 1145.	5.8	93
17	Ultra-large library docking for discovering new chemotypes. <i>Nature</i> , 2019, 566, 224-229.	13.7	595
18	Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging. <i>ACS Chemical Neuroscience</i> , 2019, 10, 384-395.	1.7	22

#	ARTICLE	IF	CITATIONS
19	Development of Novel Quinoxaline-Based μ -Opioid Receptor Agonists for the Treatment of Neuroinflammation. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 893-907.	2.9	25
20	5-HT _{2C} Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. <i>Cell</i> , 2018, 172, 719-730.e14.	13.5	185
21	Structure of the D ₂ dopamine receptor bound to the atypical antipsychotic drug risperidone. <i>Nature</i> , 2018, 555, 269-273.	13.7	341
22	Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor. <i>Cell</i> , 2018, 172, 55-67.e15.	13.5	299
23	Structural determinants of 5-HT _{2B} receptor activation and biased agonism. <i>Nature Structural and Molecular Biology</i> , 2018, 25, 787-796.	3.6	116
24	Crystal Structure of an LSD-Bound Human Serotonin Receptor. <i>Cell</i> , 2017, 168, 377-389.e12.	13.5	340
25	In silico design of novel probes for the atypical opioid receptor MRGPRX2. <i>Nature Chemical Biology</i> , 2017, 13, 529-536.	3.9	230
26	D ₄ dopamine receptor high-resolution structures enable the discovery of selective agonists. <i>Science</i> , 2017, 358, 381-386.	6.0	176
27	Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo. <i>JCI Insight</i> , 2017, 2, .	2.3	14